Cargando…
1241P Safety monitoring of adjuvant 2 weekly durvalumab for patients with stage III NSCLC: Implications for a 4 weekly regimen during the COVID-19 pandemic and beyond
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
European Society for Medical Oncology. Published by Elsevier Ltd.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506560/ http://dx.doi.org/10.1016/j.annonc.2020.08.114 |
| _version_ | 1783585042916704256 |
|---|---|
| author | Joshi, K. Muhith, A. Milner-Watts, C. Obeid, M. Khakoo, S. Bhosle, J. Minchom, A.R. O'Brien, M. |
| author_facet | Joshi, K. Muhith, A. Milner-Watts, C. Obeid, M. Khakoo, S. Bhosle, J. Minchom, A.R. O'Brien, M. |
| author_sort | Joshi, K. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7506560 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | European Society for Medical Oncology. Published by Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-75065602020-09-23 1241P Safety monitoring of adjuvant 2 weekly durvalumab for patients with stage III NSCLC: Implications for a 4 weekly regimen during the COVID-19 pandemic and beyond Joshi, K. Muhith, A. Milner-Watts, C. Obeid, M. Khakoo, S. Bhosle, J. Minchom, A.R. O'Brien, M. Ann Oncol Article European Society for Medical Oncology. Published by Elsevier Ltd. 2020-09 2020-09-22 /pmc/articles/PMC7506560/ http://dx.doi.org/10.1016/j.annonc.2020.08.114 Text en Copyright © 2020 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Article Joshi, K. Muhith, A. Milner-Watts, C. Obeid, M. Khakoo, S. Bhosle, J. Minchom, A.R. O'Brien, M. 1241P Safety monitoring of adjuvant 2 weekly durvalumab for patients with stage III NSCLC: Implications for a 4 weekly regimen during the COVID-19 pandemic and beyond |
| title | 1241P Safety monitoring of adjuvant 2 weekly durvalumab for patients with stage III NSCLC: Implications for a 4 weekly regimen during the COVID-19 pandemic and beyond |
| title_full | 1241P Safety monitoring of adjuvant 2 weekly durvalumab for patients with stage III NSCLC: Implications for a 4 weekly regimen during the COVID-19 pandemic and beyond |
| title_fullStr | 1241P Safety monitoring of adjuvant 2 weekly durvalumab for patients with stage III NSCLC: Implications for a 4 weekly regimen during the COVID-19 pandemic and beyond |
| title_full_unstemmed | 1241P Safety monitoring of adjuvant 2 weekly durvalumab for patients with stage III NSCLC: Implications for a 4 weekly regimen during the COVID-19 pandemic and beyond |
| title_short | 1241P Safety monitoring of adjuvant 2 weekly durvalumab for patients with stage III NSCLC: Implications for a 4 weekly regimen during the COVID-19 pandemic and beyond |
| title_sort | 1241p safety monitoring of adjuvant 2 weekly durvalumab for patients with stage iii nsclc: implications for a 4 weekly regimen during the covid-19 pandemic and beyond |
| topic | Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506560/ http://dx.doi.org/10.1016/j.annonc.2020.08.114 |
| work_keys_str_mv | AT joshik 1241psafetymonitoringofadjuvant2weeklydurvalumabforpatientswithstageiiinsclcimplicationsfora4weeklyregimenduringthecovid19pandemicandbeyond AT muhitha 1241psafetymonitoringofadjuvant2weeklydurvalumabforpatientswithstageiiinsclcimplicationsfora4weeklyregimenduringthecovid19pandemicandbeyond AT milnerwattsc 1241psafetymonitoringofadjuvant2weeklydurvalumabforpatientswithstageiiinsclcimplicationsfora4weeklyregimenduringthecovid19pandemicandbeyond AT obeidm 1241psafetymonitoringofadjuvant2weeklydurvalumabforpatientswithstageiiinsclcimplicationsfora4weeklyregimenduringthecovid19pandemicandbeyond AT khakoos 1241psafetymonitoringofadjuvant2weeklydurvalumabforpatientswithstageiiinsclcimplicationsfora4weeklyregimenduringthecovid19pandemicandbeyond AT bhoslej 1241psafetymonitoringofadjuvant2weeklydurvalumabforpatientswithstageiiinsclcimplicationsfora4weeklyregimenduringthecovid19pandemicandbeyond AT minchomar 1241psafetymonitoringofadjuvant2weeklydurvalumabforpatientswithstageiiinsclcimplicationsfora4weeklyregimenduringthecovid19pandemicandbeyond AT obrienm 1241psafetymonitoringofadjuvant2weeklydurvalumabforpatientswithstageiiinsclcimplicationsfora4weeklyregimenduringthecovid19pandemicandbeyond |